NGENLA

A Once-Weekly Human Growth Hormone Analog

NGENLA® (somatrogon-ghla) is approved by the U.S. FDA for the treatment of pediatric patients aged 3+ who have growth failure due to inadequate secretion of endogenous growth hormone.

One in 4,000 - 10,000

Children are affected by growth hormone deficiency, a rare disease that delays or restricts growth caused by genetic mutations or as a disease acquired after birth¹

¹ Source: Medline Plus https://medlineplus.gov/genetics/condition/isolated-growth-hormone-deficiency/ ⮑

We Believe NGENLA® is Positioned to Gain Significant Global Market Share

Better
Adherence

The market is expected to consolidate from 7 daily treatment options to 3 long-acting therapies

Growing Global Market

Estimated at $7.5 billion currently, the market is expected to grow by 8.5% annually²

Expanding Commercial Reach

NGENLA® is approved in 40 markets worldwide for pediatric patients who are affected by growth hormone deficiency

Proudly Partnered with Pfizer

Pfizer is leading the global commercialization while pursuing label expansions to reach more children who may benefit from NGENLA®

Visit NGENLA Website

²“Human Growth Hormone Market Size,” Grand View Research, Grand View Research, https://www.grandviewresearch.com/industry-analysis/human-growth-hormone-drugs-market⮑